The estimated Net Worth of Ryan Spencer is at least $4.05 Миллион dollars as of 10 February 2024. Mr Spencer owns over 20,833 units of Dynavax Technologies stock worth over $2,316,324 and over the last 5 years he sold DVAX stock worth over $877,620. In addition, he makes $859,990 as CEO & Director at Dynavax Technologies.
Mr has made over 9 trades of the Dynavax Technologies stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 20,833 units of DVAX stock worth $227,288 on 10 February 2024.
The largest trade he's ever made was exercising 89,250 units of Dynavax Technologies stock on 10 February 2022 worth over $973,718. On average, Mr trades about 20,149 units every 81 days since 2019. As of 10 February 2024 he still owns at least 212,312 units of Dynavax Technologies stock.
You can see the complete history of Mr Spencer stock trades at the bottom of the page.
Ryan Spencer is the CEO & Director at Dynavax Technologies.
As the CEO & Director of Dynavax Technologies, the total compensation of Mr Spencer at Dynavax Technologies is $859,990. There are no executives at Dynavax Technologies getting paid more.
Mr Spencer is 43, he's been the CEO & Director of Dynavax Technologies since . There are 4 older and 1 younger executives at Dynavax Technologies. The oldest executive at Dynavax Technologies Corp. is Michael S. Ostrach, 69, who is the Advisor.
Ryan's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, STE 101, SAN DIEGO, CA, 92121.
Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... и James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Dynavax Technologies executives and other stock owners filed with the SEC include: